Zogenix Begins Relday(TM) Clinical Trial for Schizophrenia

Zogenix Begins Relday(TM) Clinical Trial for Schizophrenia

Patient Screening and Enrollment Underway With Results Anticipated Before Year-End

First-in-Class Needle-Free Once-Monthly Formulation Using DosePro® Delivery System

SAN DIEGO, July 12, 2012 -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has initiated its first IND clinical trial for Relday™, a product candidate based on a combination of its DosePro® needle-free, subcutaneous drug delivery system with a proprietary, subcutaneous once-monthly formulation of risperidone for treating schizophrenia. The Phase 1 clinical trial for Relday is a single-center, open-label, safety and pharmacokinetic (PK) trial that will enroll 30 patients with chronic, stable schizophrenia or schizoaffective disorder. Zogenix expects that study results will be available by the end of 2012. Further study information can be found at http://www.clinicaltrials.gov and reference NCT01592110.

Roger L. Hawley, chief executive officer of Zogenix, said, "Relday represents a significant opportunity to leverage our proprietary DosePro needle-free drug delivery system in combination with a novel long-acting formulation of an established antipsychotic to provide psychiatrists and their patients with an improved treatment option. We look forward to completing this trial by the end of the year which we believe will enable us to begin discussions with potential partners for rest-of-world development and commercialization."

Risperidone is one of the most widely prescribed medications used to treat the symptoms of schizophrenia in adults and teenagers 13 years of age and older. The global long-acting injectable antipsychotic market was approximately $2 billion in 2011, with currently approved products using a 21-gauge or larger needle for intramuscular injections. The leading product in the category requires twice-a-month dosing and drug reconstitution prior to use. The combined market for oral and injectable antipsychotic products was estimated at more than $16 billion in 2010.

If approved, Relday will be the first subcutaneous, needle-free antipsychotic product that allows for once-monthly dosing. Zogenix believes that Relday will offer an improved pharmacokinetic profile, significant reduction in injection volume and a simplified dosing regimen due to DURECT's (Nasdaq:DRRX) SABER® controlled-release depot technology in combination with Zogenix's DosePro needle-free subcutaneous drug delivery system.

About DosePro®

The DosePro system is a first-in-class, easy-to-use drug delivery system that includes a pre-filled, single dose of sterile liquid drug, and is administered subcutaneously, without a needle. The platform is currently used by Zogenix's first commercial product, SUMAVEL® DosePro®, and its investigational candidate, Relday. The Company believes that DosePro offers several benefits to patients compared to other subcutaneous delivery methods, and that it has the potential to become a preferred delivery option for patients and physicians. These benefits include less anxiety or fear due to the lack of a needle, easier disposal without the need for a sharps container, no risk of needle stick injury or contamination, an easy-to-use three step process, no need to fill or manipulate the device, reliable performance, discreet use and portability. In several clinical trials and market research studies, DosePro has been shown to be preferred by patients over conventional needle-based systems.

Zogenix has entered into an agreement with Battelle, an independent research and development organization, to co-market the DosePro technology to potential pharmaceutical and government clients with the objective of licensing the system for use with innovative therapeutics that would be enabled or enhanced by DosePro's unique needle-free delivery system. Compared to other delivery technologies, DosePro has the potential to solve the significant challenges of delivering viscous drug formulations, such as high concentration biologics, which cannot be delivered with traditional needle-based injection. The DosePro drug delivery technology is covered by more than 46 internationally issued patents extending through 2026.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ (hydrocodone bitartrate) is a novel, oral, single-entity (without acetaminophen) extended-release formulation of various strengths of hydrocodone intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix submitted an NDA to the FDA for Zohydro in May 2012. Zogenix's second DosePro investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia.

For additional information, please visit www.zogenix.com.

Forward Looking Statements

Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming" and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding development of a commercially successful product, the initiation of clinical trials and results from such trials and the timing thereof, the ability of such product to address the global anti-psychotic market, the ability to develop a once-monthly injectable product with improved pharmacokinetics and significant reduction in injection volume, ability to maintain first-in-class status, partnering opportunities for Relday outside the United States and the timing thereof, and leveraging the DosePro technology. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in Zogenix's business, including, without limitation: the uncertainties associated with the clinical development and regulatory approval of product candidates such as Relday; including potential delays in enrollment and completion of clinical trials; difficulties in identifying, negotiating, executing and carrying out strategic transactions relating to Relday; the market potential for anti-psychotics, and Zogenix's ability to compete within that market; ability to obtain and the validity and duration of patent protection and other intellectual property rights for Relday; and other risks described in the company's prior press releases and filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

SUMAVEL®, DosePro®, ReldayTM and ZohydroTM are trademarks of Zogenix, Inc.

SABER® is a trademark of DURECT Corporation.

CONTACT: Investor Contact
         Zack Kubow | The Ruth Group
         646.536.7020 | [email protected]

         Media Contact
         Victoria Aguiar | The Ruth Group
         646.536.7013 | [email protected]

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.